Tau PET in Imaging and Cognition: Healthy Adults From 55-90
Tau Positron Emission Tomography (PET) in Imaging and Cognition
Yaakov Stern
105 participants
Jun 1, 2018
OBSERVATIONAL
Conditions
Summary
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.
Eligibility
Inclusion Criteria4
- Aged 55-90
- Previously received an amyloid PET scan
- Residing near Columbia University Medical Center
- Must be willing and able to participate
Exclusion Criteria5
- Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour)
- Pregnancy
- Lactating Women
- Current, past, or anticipated exposure to radiation
- Significant active physical illness
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03372317